Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma.
Biomarker
Cholangiocarcinoma
Nerve fiber density
Oncological outcome
Journal
Liver cancer
ISSN: 2235-1795
Titre abrégé: Liver Cancer
Pays: Switzerland
ID NLM: 101597993
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
09
12
2020
accepted:
12
02
2021
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
10
7
2021
Statut:
ppublish
Résumé
Perihilar cholangiocarcinoma (pCCA) is a biliary tract cancer with a dismal prognosis, with surgery being the only chance of cure. A characteristic aggressive biological feature of pCCA is perineural growth which is defined by the invasion of cancer cells to nerves and nerve fibers. Recently, nerve fiber density (NFD) was linked to oncological outcomes in various malignancies; however, its prognostic role in pCCA remains to be elucidated. Data of 101 pCCA patients who underwent curative-intent surgery between 2010 and 2019 were included in this study. Extensive group comparisons between patients with high and low NFD were carried out, and the association of cancer-specific survival (CSS) and recurrence-free survival with NFD and other clinicopathological characteristics was assessed using univariate and multivariable cox regression models. Patients with high NFD showed a median CSS of 90 months (95% CI: 48-132, 3-year CSS = 77%, 5-year CSS = 72%) compared to 33 months (95% CI: 19-47, 3-year CSS = 46%, 5-year CSS = 32%) in patients with low NFD ( NFD has been identified as an important novel prognostic biomarker in pCCA patients. NFD alone and in combination with nodal status in particular allows to stratify pCCA patients based on their risk for inferior oncological outcomes after curative-intent surgery.
Identifiants
pubmed: 34239812
doi: 10.1159/000515303
pii: lic-0010-0260
pmc: PMC8237795
doi:
Types de publication
Journal Article
Langues
eng
Pagination
260-274Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
World J Surg. 2014 Dec;38(12):3215-21
pubmed: 25123177
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):295-308
pubmed: 25966429
Ann Surg. 2020 Sep 24;:
pubmed: 32976284
Neoplasma. 2017;64(6):840-846
pubmed: 28895408
J Investig Med. 2018 Jan;66(1):52-61
pubmed: 28912249
Surgery. 2007 May;141(5):581-8
pubmed: 17462457
Ann Transl Med. 2013 Oct;1(3):27
pubmed: 25332971
Eur J Cancer Prev. 1991 Oct;1(1):35-7
pubmed: 1842681
Chin J Cancer Res. 2016 Apr;28(2):180-6
pubmed: 27199515
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Nat Neurosci. 2019 Aug;22(8):1289-1305
pubmed: 31285612
Front Biosci (Schol Ed). 2011 Jun 01;3:1165-79
pubmed: 21622263
Mol Med Rep. 2018 Jun;17(6):8423-8431
pubmed: 29658602
Annu Rev Immunol. 2019 Apr 26;37:19-46
pubmed: 30379595
Science. 2013 Jul 12;341(6142):1236361
pubmed: 23846904
Cell Tissue Res. 1998 Nov;294(2):227-31
pubmed: 9799438
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):66-73
pubmed: 31152820
HPB (Oxford). 2012 Aug;14(8):514-22
pubmed: 22762399
Eur J Surg Oncol. 2019 Aug;45(8):1468-1478
pubmed: 31053477
Surgery. 1998 Feb;123(2):131-6
pubmed: 9481397
HPB (Oxford). 2014 Jan;16(1):56-61
pubmed: 23461754
J Pathol. 2012 Jan;226(2):185-99
pubmed: 22006671
Surgery. 2013 Jun;153(6):811-8
pubmed: 23499016
Eur J Surg Oncol. 2008 Mar;34(3):263-71
pubmed: 18042497
Oncotarget. 2017 Apr 4;8(14):22501-22512
pubmed: 28160574
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
N Engl J Med. 2007 Apr 12;356(15):1545-59
pubmed: 17429086
Gastroenterol Rep (Oxf). 2016 Jul 6;5(1):62-66
pubmed: 27389416
Ann Surg. 2009 Feb;249(2):303-9
pubmed: 19212186
Ann Surg Oncol. 2012 May;19(5):1602-8
pubmed: 21964888
Surgery. 2018 Apr;163(4):732-738
pubmed: 29336813
Am J Cancer Res. 2019 Jan 01;9(1):1-21
pubmed: 30755808
Zentralbl Chir. 2003 Nov;128(11):928-35
pubmed: 14669113
Biomed Rep. 2016 May;4(5):515-518
pubmed: 27123240
World J Surg. 2008 Nov;32(11):2395-402
pubmed: 18795245
HPB (Oxford). 2021 Jan;23(1):99-108
pubmed: 32546423
HPB (Oxford). 2020 Mar;22(3):437-444
pubmed: 31383591
Ann Surg. 1999 Dec;230(6):808-18; discussion 819
pubmed: 10615936
Cancer. 2011 Nov 1;117(21):4834-45
pubmed: 21480205
Ann Surg Oncol. 2015 Oct;22(11):3716-23
pubmed: 25777092
J Clin Med. 2021 Jan 30;10(3):
pubmed: 33573277
J Clin Med. 2020 May 08;9(5):
pubmed: 32397289
Cancer Sci. 2019 Apr;110(4):1491-1502
pubmed: 30776178
Anticancer Res. 2019 Jan;39(1):231-236
pubmed: 30591463
Langenbecks Arch Surg. 2003 Jul;388(3):194-200
pubmed: 12819970
BMC Cancer. 2015 Jul 31;15:564
pubmed: 26228433
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Ann Surg. 2013 Jul;258(1):129-40
pubmed: 23059502
J Hepatol. 2006 Jul;45(1):43-50
pubmed: 16690156
J Gastrointest Surg. 2015 Jun;19(6):1194-5
pubmed: 25895979
J Clin Oncol. 2011 Aug 10;29(23):3140-5
pubmed: 21730269
Sci Transl Med. 2014 Aug 20;6(250):250ra115
pubmed: 25143365
Clin Transl Oncol. 2021 Apr;23(4):669-681
pubmed: 32770391
Br J Surg. 2018 Jun;105(7):829-838
pubmed: 28488733